{"id":"W2137043950","doi":"10.1016/s1470-2045(15)00006-6","title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Afatinib; Erlotinib; Medicine; Clinical endpoint; Internal medicine; Lung cancer; Erlotinib Hydrochloride; Oncology; Population; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003492747,0.0002335339,0.001350148,0.00004453721,0.00009729912,0.00001038063,0.0003046327,0.0000904564,0.0001334277],"category_scores_gemma":[0.0001741514,0.0001075242,0.00009228451,0.0001591239,0.0001726234,0.00008804508,0.00005223423,0.0001090367,0.000002892664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004205942,"about_ca_system_score_gemma":0.001189816,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001877679,"about_ca_topic_score_gemma":0.0001685925,"domain_scores_codex":[0.9982089,0.0004341275,0.0005355892,0.0002670282,0.0002638419,0.0002905076],"domain_scores_gemma":[0.9976114,0.0005994525,0.0006505811,0.0006642896,0.0003278182,0.0001464419],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9791286,0.01068667,0.002162092,0.00003937075,0.0005056114,0.00001486743,0.003292011,0.00007134538,0.0003634615,0.00009852868,0.0006981763,0.002939288],"study_design_scores_gemma":[0.9307817,0.06107069,0.001151708,0.00001570981,0.002065402,0.000003483395,0.0005008799,0.0003674442,0.00176022,0.00002114295,0.002158171,0.0001034996],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9760129,0.0005500681,0.000009805794,0.0006435172,0.000720855,0.009161214,0.0001753493,0.00001866931,0.01270762],"genre_scores_gemma":[0.9970236,0.0000153502,0.0004210868,0.0002180873,0.0002644222,0.0008515902,0.0001679471,0.00002942902,0.001008429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05038402,"threshold_uncertainty_score":0.438471,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06509205628352367,"score_gpt":0.4127227631918144,"score_spread":0.3476307069082907,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}